Meropenem Aptapharma

Meropenem, the active ingredient in Meropenem Aptapharma, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, skin and soft tissue infections, meningitis, and sepsis in hospitalized patients.

GNH USA supplies Meropenem Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a carbapenem antibiotic used to treat serious Gram‑negative and Gram‑positive bacterial infections.

- Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication. - Complicated urinary tract infections: resolves infection and prevents recurrence. - Skin and soft tissue infections: provides bacterial clearance and symptom improvement. - Meningitis: penetrates cerebrospinal fluid to treat bacterial meningitis. - Sepsis: contributes to rapid bacterial clearance in systemic infection.

Adverse reactions to meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Injection site pain: discomfort at the IV site. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: especially in patients with renal impairment or pre‑existing CNS disorders. - Clostridioides difficile colitis: severe intestinal infection that can be life‑threatening.

When using meropenem, clinicians should consider several safety measures.

- Renal function: adjust dose in patients with impaired renal clearance. - Hypersensitivity: avoid in patients with known carbapenem or beta‑lactam allergy. - Pregnancy: use only if benefit outweighs potential risk; data are limited. - Concomitant valproic acid: monitor for decreased plasma levels. - Pediatric use: safety and efficacy not established in children under 3 months. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Valproic acid: may reduce valproate levels, risking seizure breakthrough. - Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic potential when combined with other ototoxic agents. - Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters.